Inpharma 1585 - 28 Apr 2007

■ Darbepoetin-α does not affect overall survival inpatients with extensive-stage small-cell lung cancer(SCLC), according to the results of a multicentre,phase III study. Data were evaluated from 600 suchtreatment-naive patients who were randomised 1:1 toreceive darbepoetin-α 300µg or placebo, every weekfor 4 weeks, followed by three-weekly dosing for21 weeks, in addition to platinum-containingchemotherapy. There was no significant difference inoverall survival with darbepoetin-α and placebo;progression-free survival was also similar fordarbepoetin-α recipients and placebo recipients.However, darbepoetin-α was associated with asignificant change from baseline in haemoglobinconcentration, compared with placebo. Furthermore,darbepoetin-α recipients had a significantly reducedrisk of blood transfusions, compared with placeborecipients.See also page 20 of this issue; 801069309 andInpharma 1579 p22; 801013918Amgen. Aranesp(Rm) "145 Study’’ Shows No Difference in Survival inPatients with Small-Cell Lung Cancer. Media Release : 20 Apr 2007.Available from: URL: http://www.amgen.com 809074659

1

Inpharma 28 Apr 2007 No. 15851173-8324/10/1585-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved